Tue, 20 Oct 2026
03:30:15 pm
Synopsis
Vishal Mega Mart shares closed at ₹96 on October 16, 2026, down 35.34% in one year. Check the 52-week high and low, quarterly results, analyst ratings and October 21 board meeting.

Vishal Mega Mart shares closed 0.26% lower at ₹96 on October 16, 2026, on the NSE. The stock touched a low of ₹94.80, its 52-week low, during the session.
Vishal Mega Mart shares have fallen 35.34% in one year and 14.64% in three months. The stock’s 52-week high is ₹149.82.
| Metric | Details |
|---|---|
| Closing price | ₹96 |
| Daily change | -0.26% |
| 52-week high | ₹149.82 |
| 52-week low | ₹94.80 |
| Market capitalisation | ₹44,927.31 crore |
Loading chart...
Vishal Mega Mart’s board will meet on October 21, 2026, to consider its quarterly results.
In the June 2026 quarter, the company reported net profit of ₹258.77 crore, up from ₹167.92 crore in March 2026. Total income rose to ₹3,760.15 crore from ₹3,138.62 crore.
The supplied ET Markets data shows a Buy consensus among 19 analysts: 12 Strong Buy, six Buy and one Strong Sell rating.
ICICI Securities’ displayed ₹140 target price dates to 2025 and may not reflect current expectations.
As of September 2026, promoters held 40.02% of the company, while foreign institutional investors held 18.75%. Domestic institutional investors held 36.44%, including mutual fund ownership of 31.75%.
Market data is based on the supplied ET Markets figures for October 16, 2026. This article is for informational purposes only and is not investment advice.
Vishal Mega Mart shares closed at ₹96 on the NSE on October 16, 2026, down 0.26% for the day.
The stock's 52-week high is ₹149.82, while its 52-week low is ₹94.80. The stock touched its 52-week low during the October 16 session.
Vishal Mega Mart shares declined 35.34% over one year and 14.64% over three months, according to the supplied data.
The company's reported market capitalisation was approximately ₹44,927.31 crore.
Vishal Mega Mart's board is scheduled to meet on October 21, 2026, to consider its quarterly results.
The company reported net profit of ₹258.77 crore in June 2026, compared with ₹167.92 crore in the March 2026 quarter, according to the supplied figures.
Total income stood at ₹3,760.15 crore in June 2026, compared with ₹3,138.62 crore in March 2026.
Of the 19 analysts cited, 12 rated the stock Strong Buy, six rated it Buy and one rated it Strong Sell. The overall consensus was Buy. Analyst opinions can change and do not guarantee future returns.
The supplied data lists an ICICI Securities target price of ₹140 from 2025. This is a historical target and may not reflect the brokerage's current outlook.
As of September 2026, promoters held 40.02%, foreign institutional investors held 18.75% and domestic institutional investors held 36.44%. Mutual funds accounted for 31.75% ownership, according to the supplied data.
That depends on its valuation, sales growth, profitability, store expansion and competitive position. Investors should assess the latest financial results and current business outlook alongside the recent share price decline. Past performance and analyst ratings do not guarantee future returns.

Financial journalist specializing in market analysis, stock research, and investment trends. Dedicated to providing accurate, timely insights for informed decision-making.
Credentials: Experienced financial journalist with expertise in equity markets and economic analysis
The information provided in this article is for educational and informational purposes only and should not be construed as financial, investment, or legal advice. welomoney does not provide personalized investment recommendations.
For detailed terms and conditions, please read our Disclaimer and Terms of Service.

L&T has begun preliminary work on the New Tashkent International Airport project after receiving a limited notice to proceed.

DLF share price has 41% upside, according to HSBC’s target. Compare Jefferies, CLSA and other broker views on sales, cash flow and valuations.

Divi's Laboratories shares rose 1.01% to Rs 9,242.50 after a positive EU opinion on Eli Lilly's weight loss drug Foundayo. See the growth outlook.

Awfis revenue target exceeds Rs 1,800 crore for FY27, with flexible workspace demand supporting growth. Expansion and execution remain key to watch.

L&T has won a contract worth over Rs 15,000 crore. The client, project scope and execution timeline remain undisclosed, leaving its revenue impact...